Qichen
Scientist, CRISPR-X at CRISPR Therapeutics | Boston, Massachusetts, United States
Qichen’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Scientist, CRISPR-X at CRISPR Therapeutics in June 2024 - Present
Scientist, Genome Engineering at Colossal Biosciences in May 2023 - May 2024
Graduate Research Fellow at Rice University in July 2019 - May 2023
Rice University, Doctor of Philosophy - PhD, November 2026
University of Science and Technology of China, Bachelor of Science - BS, November 2026
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Discover more about CRISPR TherapeuticsClinical Trial Manager at CRISPR Therapeutics
Clinical Trial Manager at CRISPR Therapeutics
(August 2025 – Present)
Research Associate at CRISPR Therapeutics || MBA Candidate at Questrom School of Business
Research Associate II at CRISPR Therapeutics
(June 2024 – Present)
Cell Therapy at CRISPR Therapeutics || MBA Candidate at WPI
Cell Therapy at CRISPR Therapeutics
(July 2023 – Present)
Senior Vice President Finance
Senior Vice President Finance at CRISPR Therapeutics
(January 2025 – Present)
Executive Director, Head of In Vivo Research | Immuno-Oncology | Cell and Gene Therapy | CRISPR | LNP Delivery | CAR-T | CTA and IND Strategy | Cross-Functional Leadership | Regulatory Interactions | AAV | Liver | Eye |
Head of In Vivo Research, Executive Director, and Immuno-Oncology Lead at CRISPR Therapeutics
(July 2024 – Present)
Senior Director at CRISPR Therapeutics
Senior Director, CRISPR-X at CRISPR Therapeutics
(Jul 2025 – Present)
What is Qichen email address?
Email Qichen at [email protected] and [email protected]. This email is the most updated Qichen's email found in 2026.
How to contact Qichen?
To contact Qichen send an email to [email protected] or [email protected]. (updated on August 31, 2025)
What company does Qichen work for?
Qichen works for CRISPR Therapeutics.
What is Qichen's role at CRISPR Therapeutics?
Qichen is Scientist, CRISPR-X
What industry does Qichen work in?
Qichen works in the Higher Education industry.